Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MECLOFENAMATE SODIUM vs ACTRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.
Relief of mild to moderate acute pain,Treatment of primary dysmenorrhea,Management of osteoarthritis,Management of rheumatoid arthritis
Mild to moderate pain,Fever
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Terminal elimination half-life 2-4 hours; prolonged to 6-12 hours in elderly or renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via cytochrome P450 enzymes, including CYP2C9 and CYP3A4.
Primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1, SULT1A3), and oxidation (CYP2E1, CYP3A4) to form the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is detoxified by glutathione.
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Renal: 90% as unchanged drug; biliary/fecal: 10% as metabolites.
>99% (primarily to albumin)
>99% bound to albumin.
0.5-1.0 L/kg (indicates extensive tissue distribution)
0.1-0.2 L/kg; indicates limited extravascular distribution.
100% (oral, well absorbed)
Oral: 70-90% (first-pass metabolism minimal); IV: 100%.
e GFR 30-59 m L/min: use with caution, reduce dose by 50%; e GFR <30 m L/min: contraindicated.
GFR <30 m L/min: Avoid use. GFR 30-50 m L/min: Reduce dose to 50% of normal, maximum 600 mg/day.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh Class B: Reduce dose by 50%; maximum 600 mg/day. Child-Pugh Class C: Contraindicated.
Not recommended for children under 14 years; for adolescents ≥14 years, same as adult dosing.
Children ≥12 years: 400 mg orally every 6-8 hours as needed; maximum 1200 mg/day. Children <12 years: Not recommended.
Initiate at lowest effective dose (50 mg twice daily); monitor renal function and GI bleeding risk.
Initiate at 200 mg every 6-8 hours; maximum 600 mg/day due to increased risk of gastrointestinal bleeding and renal impairment.
NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Meclofenamate is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Most cases involve use of acetaminophen at doses exceeding 4000 mg per day, often involving more than one acetaminophen-containing product.
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension and edema,Renal toxicity,Anaphylactoid reactions,Exacerbation of asthma,Hematologic toxicity including anemia,Hepatic enzyme elevations
Hepatotoxicity: risk increased with chronic alcohol use, liver disease, or use of other acetaminophen-containing products. Avoid exceeding 4000 mg/day. Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis. Hypersensitivity reactions: anaphylaxis.
Hypersensitivity to meclofenamate or any other NSAID,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Perioperative pain in setting of CABG surgery,Active peptic ulcer disease or gastrointestinal bleeding
Severe hepatic impairment or active liver disease. Known hypersensitivity to acetaminophen or any component of the formulation.
Avoid high-fat meals as they may delay absorption. Limit salt intake to reduce fluid retention. Do not consume alcohol as it increases the risk of GI bleeding. Meclofenamate may decrease the effectiveness of diuretics and antihypertensive medications when taken with potassium-rich foods; monitor potassium levels.
Avoid alcohol; may increase risk of GI bleeding. No specific food restrictions, but taking with food can reduce gastrointestinal irritation. Maintain adequate hydration to prevent renal impairment.
Avoid in 1st and 2nd trimester; contraindicated in 3rd trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Associated with cardiovascular malformations if used in 1st trimester.
First trimester: Based on animal studies and limited human data, possible increased risk of cardiovascular and neural tube defects. Second/third trimester: Risk of premature closure of ductus arteriosus and oligohydramnios with prolonged use. Avoid after 30 weeks gestation.
Excreted into breast milk in small amounts; M/P ratio not established. Use caution due to potential adverse effects in neonates (e.g., gastrointestinal bleeding, platelet dysfunction).
Excreted in breast milk; M/P ratio 0.15. Low oral bioavailability to infant; considered compatible with breastfeeding. Monitor infant for sedation or feeding problems.
Increased plasma volume may require dose adjustments in 2nd and 3rd trimesters, but specific studies lacking; generally avoid use. If necessary, use lowest effective dose for shortest duration.
Dose adjustment not typically required; however, due to increased renal clearance and volume of distribution in pregnancy, higher doses may be needed to achieve therapeutic effect. Use lowest effective dose for shortest duration.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) used for mild to moderate pain, dysmenorrhea, and inflammatory arthropathies. It has a higher incidence of gastrointestinal (GI) side effects, especially diarrhea, which can be dose-limiting. Monitor renal function and blood pressure, as it may cause fluid retention and worsening of hypertension. Use with caution in patients with a history of peptic ulcer disease or bleeding disorders. It is contraindicated in perioperative pain in coronary artery bypass graft (CABG) surgery.
ACTRON (ketorolac tromethamine) is a nonsteroidal anti-inflammatory drug (NSAID) for short-term management of moderate to severe acute pain, typically not exceeding 5 days due to risk of GI bleeding, renal impairment, and cardiovascular events. Avoid in patients with active peptic ulcer disease, bleeding diathesis, or advanced renal disease. Monitor renal function and signs of bleeding. Use lowest effective dose for shortest duration. May cause bronchospasm in aspirin-sensitive asthma.
Take with food or milk to reduce stomach upset.,Avoid alcohol and aspirin while taking this medication.,Report signs of GI bleeding (black, tarry stools; blood in vomit) immediately.,May cause diarrhea; notify your doctor if it becomes severe or persistent.,Do not take with other NSAIDs without consulting your doctor.,Stay hydrated, but avoid excessive salt intake to prevent fluid retention.,Inform your doctor if you have kidney disease, high blood pressure, or a history of stomach ulcers.,Do not use during pregnancy, especially in the third trimester.
Take with food or milk to reduce stomach upset.,Do not take for more than 5 days as prescribed; longer use increases risk of serious side effects.,Avoid alcohol while taking this medication to lower risk of stomach bleeding.,Report any signs of bleeding (e.g., black stools, vomiting blood), unusual bruising, or decreased urination.,Do not take with other NSAIDs (e.g., ibuprofen, naproxen) or aspirin without consulting your doctor.,Inform your doctor about all medications, especially blood thinners (e.g., warfarin) and diuretics.,If you have asthma, be aware of potential bronchospasm; seek immediate help if you have breathing trouble.,Not recommended during pregnancy, especially in the third trimester.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MECLOFENAMATE SODIUM vs ACTRON, answered by our medical review team.
MECLOFENAMATE SODIUM is a NSAID that works by Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.. ACTRON is a NSAID that works by Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MECLOFENAMATE SODIUM and ACTRON depend on the specific clinical indication. These are both NSAID agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MECLOFENAMATE SODIUM is: 50 mg or 100 mg orally three times daily; maximum 400 mg/day.. The standard adult dose of ACTRON is: Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MECLOFENAMATE SODIUM and ACTRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MECLOFENAMATE SODIUM is classified as Category C. Avoid in 1st and 2nd trimester; contraindicated in 3rd trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Associated w. ACTRON is classified as Category C. First trimester: Based on animal studies and limited human data, possible increased risk of cardiovascular and neural tube defects. Second/third trimester: Risk of premature closur. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.